Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.37 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20359888 | 1.00 | BTK (0.37) | BTKCNR2LCKMCHR1KCNH2 | |
| SCHEMBL20359566 | 0.94 | BTK (0.38) | BTKCNR2LCKMCHR1KCNH2 | |
| SCHEMBL20359889 | 0.89 | BTK (0.38) | BTKCNR2LCKMCHR1KCNH2 | |
| SCHEMBL20358719 | 0.83 | PDE1B (0.36) | BTKMCHR1KCNH2HTR2AELANE | |
| SCHEMBL20358715 | 0.83 | PDE1B (0.36) | BTKMCHR1KCNH2HTR2AELANE | |
| SCHEMBL20365228 | 0.78 | AAK1 (0.38) | BTKCNR2HTR2AELANEPDE1B | |
| SCHEMBL20358535 | 0.77 | BTK (0.47) | BTKLCK | |
| SCHEMBL20358538 | 0.77 | BTK (0.47) | BTKLCK | |
| SCHEMBL20359334 | 0.77 | BTK (0.43) | BTKLCKKCNH2 | |
| SCHEMBL20359331 | 0.77 | BTK (0.43) | BTKLCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LCK | BTK 1/4885CNR2 1439/4885LCK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.